Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Consolidated Net Income (2020 - 2025)

Vivos Therapeutics has reported Consolidated Net Income over the past 6 years, most recently at -$7.0 million for Q4 2025.

  • Quarterly Consolidated Net Income fell 145.99% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.2 million through Dec 2025, down 90.65% year-over-year, with the annual reading at -$21.2 million for FY2025, 90.64% down from the prior year.
  • Consolidated Net Income was -$7.0 million for Q4 2025 at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $17.9 million in Q4 2022 and troughed at -$7.0 million in Q2 2022.
  • The 5-year median for Consolidated Net Income is -$4.0 million (2021), against an average of -$2.3 million.
  • The largest YoY upside for Consolidated Net Income was 306.13% in 2021 against a maximum downside of 197.29% in 2021.
  • A 5-year view of Consolidated Net Income shows it stood at $12.9 million in 2021, then surged by 38.27% to $17.9 million in 2022, then crashed by 123.85% to -$4.3 million in 2023, then surged by 33.62% to -$2.8 million in 2024, then crashed by 145.99% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Consolidated Net Income are -$7.0 million (Q4 2025), -$5.4 million (Q3 2025), and -$5.0 million (Q2 2025).